Autolus Therapeutics Plc has raised a gross $80 million from a secondary offering on Nasdaq to support the ongoing clinical development of its engineered T cell therapies for cancer. After deducting expenses, the net proceeds for the company were $74.2 million. Autolus is a portfolio company of Syncona Ltd and has a pipeline of candidate products for the treatment of haematological malignancies and solid tumours.
The company made an initial public offering of shares on Nasdaq in 2018 and went back to the market the following year to raise $100.8 million.